AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33605481 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype GG+GA (rs1672717)
Number of subjects: 407
Study 33605481 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥ 50 years
Number of subjects: 407
Study 33605481 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer duration of surgery
Number of subjects: 407
Study 33605481 — intervention group
Group type: COMPARATOR
Intervention: Control group (AA genotype)
Number of subjects: 407
Study 33605647 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with family caregivers
Number of subjects: 39
Study 33605887 — intervention group
Group type: EXPERIMENTAL
Intervention: ElderTree (ET) eHealth intervention for 12 months
Number of subjects: 346
Study 33605887 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) plus laptop and internet without ET
Number of subjects: 346
Study 33605887 — intervention group
Group type: EXPERIMENTAL
Intervention: ElderTree (ET) eHealth intervention
Number of subjects: 346
Study 33606006 — intervention group
Group type: COMPARATOR
Intervention: NOACs
Number of subjects: 52032
Study 33606006 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor bleeding
Number of subjects: 52032
Study 33606006 — intervention group
Group type: EXPERIMENTAL
Intervention: CRNM bleeding
Number of subjects: 52032
Study 33606006 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 52032
Study 33606006 — intervention group
Group type: EXPERIMENTAL
Intervention: Death within 30 days after major bleed
Number of subjects: 52032
Study 33606061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraprocedural FDG perfusion PET
Number of subjects: 20
Study 33606061 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat ablation
Number of subjects: 20
Study 33606061 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum ablation margins ≥ 5 mm on perfusion PET
Number of subjects: 20
Study 33606142 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraineurs (19 participants)
Number of subjects: 38
Study 33606142 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants (19 participants)
Number of subjects: 38
Study 33606142 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of published studies
Number of subjects: 38
Study 33606269 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 400 mg Q2W
Number of subjects: 127
Study 33606269 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg Q2W
Number of subjects: 127
Study 33606269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 33606269 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 400 mg Q2W and CZP 200 mg Q2W
Number of subjects: 127
Study 33606269 — intervention group
Group type: COMPARATOR
Intervention: CZP 400 mg Q2W, CZP 200 mg Q2W, and placebo
Number of subjects: 127
Study 33606312 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal allergen challenge (NAC) with cockroach extract (0.00381-11.9 µg/mL Bla g 1)
Number of subjects: 25
Study 33606312 — intervention group
Group type: COMPARATOR
Intervention: Nasal allergen challenge (NAC) with diluent
Number of subjects: 25
Study 33606312 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal allergen challenge (NAC)
Number of subjects: 25
Study 33606312 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal allergen challenge (NAC) responders
Number of subjects: 25
Study 33606413 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard shock protocol with early invasive hemodynamic monitoring, mechanical circulatory support (MCS), and percutaneous coronary intervention (PCI)
Number of subjects: 300
Study 33606418 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation (LTVV), defined as VT of 8 ml kg-1 or less predicted bodyweight (PBW)
Number of subjects: 9864
Study 33606418 — intervention group
Group type: EXPERIMENTAL
Intervention: Median tidal volume (VT)
Number of subjects: 9864
Study 33606418 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors mediating the sex difference in use of LTVV
Number of subjects: 9864
Study 33606655 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication management app delivered via care packages
Number of subjects: 21
Study 33606655 — intervention group
Group type: EXPERIMENTAL
Intervention: Framework for Agile and Remote Operations (FAR Ops)
Number of subjects: 21
Study 33607083 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary arterial pruning
Number of subjects: 4227
Study 33607083 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent emphysema
Number of subjects: 4227
Study 33607088 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation ± antiplatelets in asymptomatic patients
Number of subjects: 52032
Study 33607088 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation ± antiplatelets in symptomatic patients
Number of subjects: 52032
Study 33607088 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic patients
Number of subjects: 52032
Study 33607088 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic patients
Number of subjects: 52032
Study 33607477 — intervention group
Group type: EXPERIMENTAL
Intervention: NBTXR3 (intratumoural injection) followed by intensity-modulated radiation therapy (IMRT; 70 Gy)
Number of subjects: 19
Study 33607632 — intervention group
Group type: EXPERIMENTAL
Intervention: Pencil-beam scanning (PBS)
Number of subjects: 0
Study 33607632 — intervention group
Group type: COMPARATOR
Intervention: Passive scattering (PS)
Number of subjects: 0
Study 33607765 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) program for LDG
Number of subjects: 98
Study 33607957 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth with remote blood pressure monitoring
Number of subjects: 0
Study 33607957 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient monitoring
Number of subjects: 0
Study 33608027 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive oocyte quality scoring based on cumulus gene expression analysis combined with morphology scoring (experimental arm, n=113)
Number of subjects: 633
Study 33608027 — intervention group
Group type: COMPARATOR
Intervention: Morphology-based embryo selection only (control arm, n=520)
Number of subjects: 633
Study 33608030 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19-related ARDS
Number of subjects: 42
Study 33608030 — intervention group
Group type: COMPARATOR
Intervention: Classical ARDS
Number of subjects: 42
Study 33608053 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-BCMA CAR T cell therapy
Number of subjects: 1
Study 33608053 — intervention group
Group type: COMPARATOR
Intervention: Lymphodepleting chemotherapy (LDC)
Number of subjects: 1
Study 33608060 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment with measurement based care (MBC)
Number of subjects: 0
Study 33608060 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPS tool for universal screening
Number of subjects: 0
Study 33608060 — intervention group
Group type: EXPERIMENTAL
Intervention: OUD Symptom Checklist and PAQ-OUD
Number of subjects: 0
Study 33608263 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Treatment
Number of subjects: 0
Study 33608375 — intervention group
Group type: EXPERIMENTAL
Intervention: Single enhancer followed by VSV injection 1 day later for aggressively growing tumors
Number of subjects: 0
Study 33608375 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple enhancers followed by VSV injection 15 days later for slow-growing tumors
Number of subjects: 0
Study 33608377 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-428 administered intravenously every 2 weeks at doses between 0.01 and 3.6 mg/kg.
Number of subjects: 59
Study 33608714 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seropositive individuals
Number of subjects: 639
Study 33608714 — intervention group
Group type: COMPARATOR
Intervention: SARS-CoV-2 seronegative individuals
Number of subjects: 639
Study 33608748 — intervention group
Group type: EXPERIMENTAL
Intervention: Nobio Infinix composite (antibacterial composite)
Number of subjects: 20
Study 33608748 — intervention group
Group type: COMPARATOR
Intervention: Control composite
Number of subjects: 20
Study 33608798 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe OSA (AHI ≥ 30)
Number of subjects: 49
Study 33608798 — intervention group
Group type: COMPARATOR
Intervention: Non-severe OSA (5 ≤ AHI ≤ 30)
Number of subjects: 49
Study 33609152 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic ability of the intervention (not specified)
Number of subjects: 15
Study 33609152 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study 33609856 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ug adjunctive estradiol treatment
Number of subjects: 56
Study 33610169 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with Habit Reversal Training (HRT) and Exposure Response Prevention (ERP)
Number of subjects: 59
Study 33610169 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with HRT and ERP (individual or group setting)
Number of subjects: 59
Study 33610169 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with HRT and ERP
Number of subjects: 59
Study 33610319 — intervention group
Group type: EXPERIMENTAL
Intervention: IV carboplatin, paclitaxel, and bevacizumab every 21 days (regimen 1)
Number of subjects: 424
Study 33610319 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly IV paclitaxel with carboplatin and bevacizumab (regimen 2)
Number of subjects: 424
Study 33610319 — intervention group
Group type: EXPERIMENTAL
Intervention: IV paclitaxel and bevacizumab with IP cisplatin (regimen 3)
Number of subjects: 424
Study 33610319 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens with veliparib (either continuous or intermittent)
Number of subjects: 424
Study 33610319 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (comparison of PFS)
Number of subjects: 424
Study 33610453 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib plus platinum doublet (n=28)
Number of subjects: 44
Study 33610453 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib plus single-agent chemotherapy (n=29)
Number of subjects: 44
Study 33610453 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib plus chemotherapy
Number of subjects: 44
Study 33610500 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical K562-mb15-41BBL-activated and expanded NK (NKAE) cells; 13 infusions administered after a lymphodepleting regimen
Number of subjects: 7
Study 33610532 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD)
Number of subjects: 692
Study 33611982 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Hepatocyte Growth Factor (HGF) levels measured on day 1
Number of subjects: 86
Study 33611982 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Hepatocyte Growth Factor (HGF) levels measured on day 3
Number of subjects: 86
Study 33611982 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of HGF with endothelial cell injury markers
Number of subjects: 86
Study 33611982 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause 28-day mortality
Number of subjects: 86
Study 33612381 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded retrospective continuous glucose monitoring (rCGM)
Number of subjects: 102
Study 33612455 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg, every 3 weeks)
Number of subjects: 95
Study 33613286 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors
Number of subjects: 0
Study 33613318 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized dietary fat intake (20 kcal⋅kgFFM)
Number of subjects: 0
Study 33613417 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded Home-Based Telerehabilitation
Number of subjects: 0
Study 33613422 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 0
Study 33613422 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 33613701 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor monotherapy
Number of subjects: 58
Study 33613701 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of baseline lesion number (BLN) and tumor mutation burden (TMB)
Number of subjects: 58
Study 33614477 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral prophylaxis
Number of subjects: 170
Study 33614477 — intervention group
Group type: COMPARATOR
Intervention: No antiviral prophylaxis (Control)
Number of subjects: 170
Study 33614504 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bortezomib, cyclophosphamide, and dexamethasone with daratumumab
Number of subjects: 0
Study 33614504 — intervention group
Group type: COMPARATOR
Intervention: Combination of bortezomib, cyclophosphamide, and dexamethasone without daratumumab
Number of subjects: 0
Study 33614888 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg daily for 24 weeks
Number of subjects: 50
Study 33614888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 33615207 — intervention group
Group type: EXPERIMENTAL
Intervention: NASH patients with pronounced insulin resistance (IR)
Number of subjects: 0
Study 33615207 — intervention group
Group type: COMPARATOR
Intervention: NASH patients
Number of subjects: 0
Study 33615399 — intervention group
Group type: EXPERIMENTAL
Intervention: Macimorelin 0.5 mg/kg
Number of subjects: 28
Study 33615399 — intervention group
Group type: EXPERIMENTAL
Intervention: Macimorelin 0.75 mg/kg
Number of subjects: 28
Study 33615630 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride (2 mg)
Number of subjects: 17
Study 33615630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 33615833 — intervention group
Group type: EXPERIMENTAL
Intervention: E-hookah vaping
Number of subjects: 26
Study 33615833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid infusion
Number of subjects: 26
Study 33615833 — intervention group
Group type: COMPARATOR
Intervention: Sham-vaping control
Number of subjects: 26
Study 33616178 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous peripheral nerve stimulation (PNS) for 60 days
Number of subjects: 15
Study 33616178 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous peripheral nerve stimulation (PNS) after 5 months
Number of subjects: 15
Study 33616229 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert Ultra
Number of subjects: 3500
Study 33616229 — intervention group
Group type: COMPARATOR
Intervention: Xpert MTB/RIF
Number of subjects: 3500
Study 33616416 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal bevacizumab 2.5 mg/kg
Number of subjects: 13
Study 33616416 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal bevacizumab 5 mg/kg
Number of subjects: 13
Study 33616416 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal bevacizumab 7.5 mg/kg
Number of subjects: 13
Study 33616416 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal bevacizumab (all doses)
Number of subjects: 13
Study 33616547 — intervention group
Group type: EXPERIMENTAL
Intervention: Getting Off app (immediate delivery, n=150)
Number of subjects: 300
Study 33616547 — intervention group
Group type: COMPARATOR
Intervention: Getting Off app (delayed delivery, n=150)
Number of subjects: 300
Study 33616547 — intervention group
Group type: COMPARATOR
Intervention: Historical matched sample (n=~600) from brick-and-mortar group-based Getting Off intervention
Number of subjects: 300
Study 33616753 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise (FM)
Number of subjects: 94
Study 33616753 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric exercise (FM)
Number of subjects: 94
Study 33616753 — intervention group
Group type: COMPARATOR
Intervention: Isometric exercise (CON)
Number of subjects: 94
Study 33616753 — intervention group
Group type: COMPARATOR
Intervention: Concentric exercise (CON)
Number of subjects: 94
Study 33616753 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (FM and CON)
Number of subjects: 94
Study 33616753 — intervention group
Group type: EXPERIMENTAL
Intervention: FM
Number of subjects: 94
Study 33616758 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximetry-derived peripheral perfusion index (PPI) after 200 mL crystalloid challenge
Number of subjects: 58
Study 33616758 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid challenge test using 200 mL crystalloid solution
Number of subjects: 58
Study 33616758 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional 300 mL crystalloid infusion
Number of subjects: 58
Study 33616875 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-mixture insulin analog (MMI)
Number of subjects: 0
Study 33616875 — intervention group
Group type: COMPARATOR
Intervention: Basal insulin (BI)
Number of subjects: 0
Study 33617291 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomechanical analysis during double-leg drop jump
Number of subjects: 1045
Study 33617291 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomechanical analysis during unplanned change of direction (CoD)
Number of subjects: 1045
Study 33617291 — intervention group
Group type: COMPARATOR
Intervention: Commonly reported return-to-play strength, jump, and timed CoD performance measures
Number of subjects: 1045
Study 33617291 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate regression modeling
Number of subjects: 1045
Study 33617672 — intervention group
Group type: EXPERIMENTAL
Intervention: DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1)
Number of subjects: 0
Study 33617781 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33617813 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-menopausal women
Number of subjects: 245
Study 33617813 — intervention group
Group type: COMPARATOR
Intervention: Pre-menopausal women
Number of subjects: 245
Study 33618265 — intervention group
Group type: EXPERIMENTAL
Intervention: Undernutrition (stunting or thinness)
Number of subjects: 1385
Study 33618265 — intervention group
Group type: EXPERIMENTAL
Intervention: Median age of puberty onset for girls
Number of subjects: 1385
Study 33618265 — intervention group
Group type: EXPERIMENTAL
Intervention: Median age of puberty onset for boys
Number of subjects: 1385
Study 33618265 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at first menarche for girls
Number of subjects: 1385
Study 33618265 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient deficiency
Number of subjects: 1385
Study 33618437 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fludarabine and cyclophosphamide combined with rituximab (FCR); fludarabine reduced to 12 mg/m²
Number of subjects: 107
Study 33618920 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperuricemic group (SUA ≥7 mg/dL in men and ≥6 mg/dL in women)
Number of subjects: 10537
Study 33618920 — intervention group
Group type: EXPERIMENTAL
Intervention: Each increase in SUA
Number of subjects: 10537
Study 33618925 — intervention group
Group type: EXPERIMENTAL
Intervention: MetS-related dietary pattern (MetS-DP) characterized by high intakes of processed meat and desserts, and low intakes of vegetables, tea, rice, fruits, milk, and meat substitutes
Number of subjects: 429
Study 33619044 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Cycling Work Rosters (RCWRs) with shifts ≤16 hours
Number of subjects: 294
Study 33619044 — intervention group
Group type: COMPARATOR
Intervention: Extended-Duration Work Rosters (EDWRs) with shifts of 24+ hours
Number of subjects: 294
Study 33619368 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-BCMA CAR T cell therapy
Number of subjects: 168
Study 33619368 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 168
Study 33619369 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab, carfilzomib, lenalidomide, and dexamethasone combination
Number of subjects: 41
Study 33619369 — intervention group
Group type: EXPERIMENTAL
Intervention: CRISPR-Cas9 deletion of PPIA or inhibition of PPIA with ciclosporin
Number of subjects: 41
Study 33619600 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 (55 kBq/kg, three administrations)
Number of subjects: 10
Study 33619600 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223
Number of subjects: 10
Study 33619893 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically stable periods (CSP)
Number of subjects: 900
Study 33619977 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse pregnancy outcomes/Gestational diabetes mellitus (APO/GDM)
Number of subjects: 4471
Study 33620177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic treatment interruption (CTI) of rosuvastatin for 72 weeks (3 treatment-interruption cycles)
Number of subjects: 10
Study 33620177 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study 33620327 — intervention group
Group type: EXPERIMENTAL
Intervention: imitoMeasure app
Number of subjects: 61
Study 33620327 — intervention group
Group type: COMPARATOR
Intervention: acetate tracing
Number of subjects: 61
Study 33620330 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app (SweetGoals) with incentives for adherence
Number of subjects: 300
Study 33620330 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app (SweetGoals) with web health coaching
Number of subjects: 300
Study 33620330 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app (SweetGoals) as core intervention
Number of subjects: 300
Study 33620373 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental factors (precipitation, temperature, relative humidity)
Number of subjects: 114067
Study 33620373 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental factors (precipitation)
Number of subjects: 114067
Study 33620373 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm and wet environments
Number of subjects: 114067
Study 33620378 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative screening for postoperative MACE with serial measurements of cardiac troponin
Number of subjects: 2265
Study 33620378 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD
Number of subjects: 2265
Study 33620378 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodynamically relevant arrhythmias
Number of subjects: 2265
Study 33620378 — intervention group
Group type: EXPERIMENTAL
Intervention: AHF
Number of subjects: 2265
Study 33620378 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous MI
Number of subjects: 2265